CORPUS PHARMA
ActiveSummary
CORPUS PHARMA has been active since 2008 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €66,467 and a net result of -€11,153. Equity is growing by about 25% per year across the filed financial years. Its solvency ranks better than 89% of 22,679 sector peers (NACE 47, financial year 2025). The computed 12-month bankruptcy probability is 0.1% (very low).
History
Acts, filings and financial milestones
14-08
Gazette deed
Resignation: Koenraad Huyghe (manager)Appointment: Koenraad Huyghe (director) · Capital conversion · Amendment of the articles11 facts ▸
- Other provision, 27-04-2023
- General meeting, 26-04-2023
- Other provision, “aanpassing statuten en behoud rechtsvorm, aanpassen en behouden” (deed in Dutch)
- Capital conversion, “statutair onbeschikbare eigen vermogensrekening”, EUR (deed in Dutch)
- Other provision, “wettelijke reserve” (deed in Dutch)
- Amendment of the articles
- Capital
- Director resignation, Koenraad Huyghe (manager)
- Director appointment, Koenraad Huyghe (director (not named in the articles))
- Director discharge, Koenraad Huyghe
- Registered office clause, “8980 Zonnebeke (Beselare),Slangenmeersstraat 9” (deed in Dutch)
About the unread acts
Of the 4 Belgian Official Gazette deeds we know for this company, 1 has been read. The other 3 have not been read yet: what they contain is neither established nor disproved here.